Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.
Metrics to compare | 382150 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship382150PeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.9x | −11.3x | −0.6x | |
PEG Ratio | 0.54 | −0.12 | 0.00 | |
Price/Book | 6.7x | 3.7x | 2.6x | |
Price / LTM Sales | 121.6x | 12.9x | 3.4x | |
Upside (Analyst Target) | - | 14.2% | 41.1% | |
Fair Value Upside | Unlock | 15.7% | 5.3% | Unlock |